Reuters logo
BRIEF-Protagonist Therapeutics signs deal with J&J to develop bowel drug
2017年5月30日 / 上午11点22分 / 6 个月前

BRIEF-Protagonist Therapeutics signs deal with J&J to develop bowel drug

May 30 (Reuters) - Protagonist Therapeutics Inc

* Protagonist therapeutics enters into worldwide agreement with janssen to co-develop and commercialize ptg-200 for inflammatory bowel disease

* Protagonist therapeutics -to receive a $50 million upfront payment and potentially up to an additional $940 million in development and sales milestones

* Protagonist therapeutics inc says under terms of agreement, double-digit tiered royalties on net sales

* Protagonist therapeutics inc says protagonist and janssen to co-fund development through phase 2

* Protagonist therapeutics inc says co retains option to co-detail u.s. Prescribers Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below